Brief: SanBio Says U.S. FDA Granted Regenerative Medicine Advanced Therapy Designation For SB623

SanBio

19/09/2019 09:14

Sept 19 (Reuters) - SanBio Co Ltd  4592.T :
    * SANBIO GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY
DESIGNATION FROM THE U.S. FDA FOR SB623 FOR THE TREATMENT OF
CHRONIC NEUROLOGICAL MOTOR DEFICITS SECONDARY TO TRAUMATIC BRAIN
INJURY
    * SANBIO CO -EXPECTS TO INITIATE PHASE 3 TRIAL FOR SB623  BY
END
OF FY ENDING JAN 31, 2021

Source text for Eikon:  ID:nBw62Q1RNa 
Further company coverage:  4592.T 

 ((Reuters.Briefs@thomsonreuters.com;))